CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain...
Brain
Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer
Cover Image Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer...
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a...
Leading Plastic Surgeons Spotlight “Active Tension Offloading” as Emerging Standard in Surgical Closure at ASAPS
At The Aesthetic MEET, hosted by The Aesthetic Society (ASAPS), leading plastic surgeons explored the critical role of tension management...
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with...
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorderFive...
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building...
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not...
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents...
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of...
AltaPointe Health Child Psychiatrist Explains New Surgeon General Advisory About Children’s Screen Time
MOBILE, Ala., June 10, 2026 /PRNewswire/ -- A new advisory from the U.S. Surgeon General is encouraging parents to take...
M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...
M2M Healthcare Market Size to Reach USD 28.77 Billion by 2031 Driven by Connected Healthcare and Remote Monitoring Adoption | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of M2M Healthcare?According to Valuates Reports, The global...
Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...
Digital Medical Partnerships Market Size to Reach USD 3.76 Billion by 2031 Driven by Healthcare Digital Transformation and Connected Care Growth | Valuates Reports
BANGALORE, India, June 10, 2026 /PRNewswire/ -- What is the Market Size of Digital Medical Partnerships?According to Valuates Reports, The...
Early Brain Aneurysm Foundation Funding Helps Drive Breakthrough in Understanding How Brain Aneurysms Form and Weaken
New UCSF study, published today in Nature Neuroscience, identifies a destructive cellular process that weakens artery walls and could help...
Early Brain Aneurysm Foundation Funding Helps Drive Breakthrough in Understanding How Brain Aneurysms Form and Weaken
New UCSF study, published today in Nature Neuroscience, identifies a destructive cellular process that weakens artery walls and could help...
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance...
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a potentially disease-modifying approach...
AI IS A FORCE MULTIPLIER FOR NEUROPATHOLOGY AT UC DAVIS
DEMENTIA RESEARCH IS SUPPORTED BY A GIFT FROM SUSAN AND CHARLES BERGHOFF FOUNDATIONMORGAN HILL, Calif., June 9, 2026 /PRNewswire/ --...